Literature DB >> 25230219

The impact of dementia development concurrent with Parkinson's disease: a new perspective.

Alyce Russell, Alesya Drozdova, Wei Wang, Meghan Thomas1.   

Abstract

Dementia is the leading cause of disability worldwide among chronic diseases in the elderly and is a major contributor to mortality. Importantly, dementia that develops as a comorbid condition significantly compounds the burden of disease on the person, their caregivers and the health care system. Dementia is a frequent comorbidity of Parkinson's disease (PD) and about 80% of people with PD will develop dementia during the course of the disease. Incidence of dementia in PD ranges from 54.7 to 107.14 per 1000 person-years while point prevalence estimates range from 19.7 to 35.3%. The range in incidence and point prevalence can be attributed to varying diagnostic criteria, sample biases, and sample size. Nosologically, there is still disagreement on the origins of dementia in PD. Dementia development may be most often caused by the progression of PD-type pathology; however, the occurrence of Alzheimer's disease (AD)-type pathology suggests that an interplay exists between the genes and proteins associated with PD and AD. Furthermore, these genes and proteins may increase the risk and severity of dementia development in people with PD. Understanding the mechanisms of neurodegeneration in PD and AD may, therefore, improve efforts to manage and treat PD dementia. Given this, it is important to adequately define the frequency of PD dementia for informed decision making, particularly in the areas of aged-care and government health policy.

Entities:  

Mesh:

Year:  2014        PMID: 25230219     DOI: 10.2174/1871527313666140917122739

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  7 in total

Review 1.  Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview.

Authors:  Khurshid Ahmad; Mohammad Hassan Baig; Gohar Mushtaq; Mohammad Amjad Kamal; Nigel H Greig; Inho Choi
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

2.  Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jia-Wei Wang; Yu-Qing Zhang; Xiao-Hua Zhang; Yun-Peng Wang; Ji-Ping Li; Yong-Jie Li
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

3.  From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms.

Authors:  Sara Redenšek; Vita Dolžan; Tanja Kunej
Journal:  OMICS       Date:  2018-01

4.  Translation and cross-cultural validation of a precision health tool, the Suboptimal Health Status Questionnaire-25, in Korean.

Authors:  Zheng Guo; Ruoyu Meng; Yulu Zheng; Xingang Li; Ziqi Zhou; Leilei Yu; Qian Tang; Ying Zhao; Monique Garcia; Yuxiang Yan; Manshu Song; Lois Balmer; Jun Wen; Haifeng Hou; Xuerui Tan; Wei Wang
Journal:  J Glob Health       Date:  2022-10-01       Impact factor: 7.664

5.  Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe.

Authors:  Daniel M Mason; Negin Nouraei; Deepti B Pant; Kristin M Miner; Daniel F Hutchison; Kelvin C Luk; John F Stolz; Rehana K Leak
Journal:  Mol Neurodegener       Date:  2016-06-30       Impact factor: 14.195

6.  Risk of dementia after Parkinson's disease in Taiwan: a population-based retrospective cohort study using National Health Insurance claims.

Authors:  Chung-Yi Li; Susan C Hu; Chih-Ching Liu; Yu Sun; Pei-Chen Lee
Journal:  BMJ Open       Date:  2019-03-03       Impact factor: 2.692

7.  Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.

Authors:  Lindsay E Stoyka; Andrew E Arrant; Drake R Thrasher; Dreson L Russell; Jennifer Freire; Casey L Mahoney; Ashwin Narayanan; Aseel G Dib; David G Standaert; Laura A Volpicelli-Daley
Journal:  Neurobiol Dis       Date:  2019-12-16       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.